Refined Chelator Spacer Moieties Ameliorate the Pharmacokinetics of PSMA-617

Prostate-specific membrane antigen (PSMA) binding tracers are promising agents for the targeting of prostate tumors. To further optimize the clinically established radiopharmaceutical PSMA-617, novel PSMA ligands for prostate cancer endoradiotherapy were developed. A series of PSMA binding tracers t...

Full description

Bibliographic Details
Published in:	Frontiers in Chemistry
Main Authors:	José Carlos dos Santos, Martin Schäfer, Ulrike Bauder-Wüst, Barbro Beijer, Matthias Eder, Karin Leotta, Christian Kleist, Jan-Philip Meyer, Thomas R. Dilling, Jason S. Lewis, Clemens Kratochwil, Klaus Kopka, Uwe Haberkorn, Walter Mier
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-08-01
Subjects:	PSMA prostate cancer PET imaging endoradiotherapy chelator
Online Access:	https://www.frontiersin.org/articles/10.3389/fchem.2022.898692/full

Similar Items

A New Class of PSMA-617-Based Hybrid Molecules for Preoperative Imaging and Intraoperative Fluorescence Navigation of Prostate Cancer
by: Ann-Christin Eder, et al.
Published: (2022-02-01)

Editorial: Theranostics as a driving force in nuclear medicine
by: Steven P. Rowe, et al.
Published: (2024-09-01)

Ac-EAZY! Towards GMP-Compliant Module Syntheses of <sup>225</sup>Ac-Labeled Peptides for Clinical Application
by: Marc Pretze, et al.
Published: (2021-07-01)

Human ABC and SLC Transporters: The Culprit Responsible for Unspecific PSMA-617 Uptake?
by: Harun Taş, et al.
Published: (2024-04-01)

[<sup>177</sup>Lu]Lu-PSMA-617 (Pluvicto<sup>TM</sup>): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer
by: Ute Hennrich, et al.
Published: (2022-10-01)

Integration of CT urography improves diagnostic confidence of 68Ga-PSMA-11 PET/CT in prostate cancer patients
by: Leon Will, et al.
Published: (2017-12-01)

Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225
by: Catherine Meyer, et al.
Published: (2022-10-01)

Synthesis and characterization of holmium acetylacetonate nanoparticles for nuclear medicine applications
by: K Yavari, et al.
Published: (2020-02-01)

Radiopharmaceuticals for Treatment of Adrenocortical Carcinoma
by: Kerstin Michalski, et al.
Published: (2023-12-01)

[<sup>68</sup>Ga]Ga-PSMA-11: The First FDA-Approved <sup>68</sup>Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer
by: Ute Hennrich, et al.
Published: (2021-07-01)

The efficacy and safety of 225Ac-PSMA-617 in metastatic castration-resistant prostate cancer
by: Jiao Ma, et al.
Published: (2025-02-01)

Hematological toxicity of [225Ac]Ac-PSMA-617 and [177Lu]Lu-PSMA-617 in RM1-PGLS syngeneic mouse model
by: Meryl Maria Vilangattil, et al.
Published: (2025-03-01)

A pilot study of 68 Ga-PSMA-617 PET/CT imaging and 177Lu-EB-PSMA-617 radioligand therapy in patients with adenoid cystic carcinoma
by: Guochang Wang, et al.
Published: (2022-08-01)

Lutetium-177-PSMA-617: A Vision of the Future
by: Elias Chandran, et al.
Published: (2022-12-01)

Preliminary clinical study of p-iodo benzoyl moiety-modified PSMA inhibitors and prospective comparison with 68Ga-PSMA-11
by: Jianpeng Cao, et al.
Published: (2025-06-01)

Comparison of 18F-DCFPyL and 68Ga-PSMA-11 for 177Lu-PSMA-617 therapy patient selection
by: Surekha Yadav, et al.
Published: (2024-06-01)

Preclinical comparison of [177Lu]Lu-rhPSMA-10.1 and [177Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studies
by: Alexander Wurzer, et al.
Published: (2024-02-01)

Pretherapeutic PSMA PET-Derived Semiquantitative Parameters as Predictors of PSA Response in Patients with mCRPC Receiving [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy
by: Dheeratama Siripongsatian, et al.
Published: (2024-10-01)

Up-Regulation of PSMA Expression In Vitro as Potential Application in Prostate Cancer Therapy
by: Roswitha Runge, et al.
Published: (2023-04-01)

[<sup>89</sup>Zr]Zr-PSMA-617 PET/CT in a Patient with Biochemical Recurrence of Prostate Cancer and Prior Indetermined Findings on [<sup>18</sup>F]PSMA-1007 Imaging
by: Moritz B. Bastian, et al.
Published: (2024-10-01)

Comment on “PSMA response evaluation in follow-up PSMA-PET/CT after stereotactic ablative body radiotherapy (SABR) for oligometastases in prostate cancer”
by: Parth Aphale, et al.
Published: (2025-11-01)

Radiation safety and dialysate analysis in hemodialysis following Lu-177-PSMA-617 therapy: A case report
by: Yu-Yi Huang, et al.
Published: (2025-01-01)

Deep learning and radiomics framework for PSMA-RADS classification of prostate cancer on PSMA PET
by: Kevin H. Leung, et al.
Published: (2022-12-01)

The therapeutic use of 177 Lu-PSMA-617 radioligand therapy in prostate cancer treatment: a review of literature and ongoing trials
by: Alexander Konopnicki, et al.
Published: (2024-12-01)

Characterization of Non-Specific Uptake and Retention Mechanisms of [<sup>177</sup>Lu]Lu-PSMA-617 in the Salivary Glands
by: Nathalie Heynickx, et al.
Published: (2023-05-01)

Bibliometric and scientometric analysis of PSMA-targeted radiotheranostics: knowledge mapping and global standing
by: Mohamed Sallam, et al.
Published: (2024-07-01)

Different PSMA Radiopharmaceuticals: A Comparative Study of [<sup>18</sup>F]F-PSMA-1007, [<sup>18</sup>F]F-JK-PSMA-7, and [<sup>99m</sup>Tc]Tc-PSMA-I&S in the Skeletal System
by: Zsófia Sára Mikó, et al.
Published: (2024-10-01)

Early treatment response assessment with [177Lu]PSMA whole-body-scintigraphy compared to interim PSMA-PET
by: David Ventura, et al.
Published: (2024-09-01)

Histologically Confirmed Testicular Metastasis Revealed by [<sup>89</sup>Zr]Zr-PSMA-617 PET/CT in a Patient with Biochemical Recurrence of Prostate Cancer and Negative Conventional PSMA PET/CT Imaging
by: Florian Rosar, et al.
Published: (2023-04-01)

[68Ga]Ga-PSMA PET/MRI, histological PSMA expression and preliminary experience with [177Lu]Lu-PSMA therapy in relapsing high-grade glioma
by: Peter Truckenmueller, et al.
Published: (2022-09-01)

Current status of PSMA-targeted imaging and therapy
by: Hui Wang, et al.
Published: (2024-01-01)

Preclinical investigations and first-in-human application of 152Tb-PSMA-617 for PET/CT imaging of prostate cancer
by: Cristina Müller, et al.
Published: (2019-07-01)

Total Tumor Volume on <sup>18</sup>F-PSMA-1007 PET as Additional Imaging Biomarker in mCRPC Patients Undergoing PSMA-Targeted Alpha Therapy with <sup>225</sup>Ac-PSMA-I&T
by: Lena M. Unterrainer, et al.
Published: (2022-04-01)

[225Ac]Ac-PSMA-617 production method: development of an efficient and reproducible radiolabelling process for establish a clinical routine production
by: Michela Aurilio, et al.
Published: (2025-05-01)

Tubarial salivary glands on PSMA ligands based PET imaging and post 177Lu PSMA therapy scan: reiterating its importance
by: Srinivas Kumar, et al.
Published: (2024-01-01)

Tolerability of concurrent external beam radiotherapy and [177Lu]Lu-PSMA-617 for node-positive prostate cancer in treatment naïve patients, phase I study (PROQURE-I trial)
by: Esmée C. A. van der Sar, et al.
Published: (2023-03-01)

Hematological Toxicity in Mice after High Activity Injections of <sup>177</sup>Lu-PSMA-617
by: Amanda Kristiansson, et al.
Published: (2022-03-01)

Acute pancreatitis and biliary obstruction from metastatic lymph node compression during [177Lu] Lu-PSMA-617 therapy: a case report
by: Gokce Belge Bilgin, et al.
Published: (2024-10-01)

Development of a homotrimeric PSMA radioligand based on the NOTI chelating platform
by: Sebastian Martin, et al.
Published: (2024-12-01)

Differences in Distribution and Detection Rate of the [<sup>68</sup>Ga]Ga-PSMA Ligands PSMA-617, -I&T and -11—Inter-Individual Comparison in Patients with Biochemical Relapse of Prostate Cancer
by: Falk Gühne, et al.
Published: (2021-12-01)